HIDDEN PRECIOUS GEM --- ARVIND REMEDIES LTD (BSE CODE : 531823)
STOCK : ARVIND REMEDIES LTD. Trading in BSE Code : 531823.
Promoters Buying Heavily….. Increasing Stake
Target : 5.5/- to 7.5/- in Short term and Medium terms
Equity : 26 Cr
Promoters Holding : 25% (Buying Heavily by promoters to increase stake); Financial Institutions and Banks and Body Corporate : 13%.
Face Value : 1/-
EPS : 1/- above (As per 20010-11 June Quarter) Estimate d EPS for Full Year above 1.5/- ( Expansion Income will Add)
Book Value: 2.9/-
Dividend History : 2010 --- 5%; 2009 --- 5%; 2008 --- 5%; 2007 --- 5%; 2006 --- 5%
Arvind Remedies Ltd doing Pharma Business; Recently all Pharma Stocks up 50% to 100% by future Growth. Arvind Remedies also in Pharma Business and Expanding Business more and more and Having Good Land Bank and Valuable Assets. So Soon Stock will go 5/- to 7/- minimum.
Arvind Remedies Ltd Expanding plans is very Aggressive. Unit 2 Income and netProfit will come this Quarter onwards. And The project is being implemented to manufacture principally, the injectables (vials and ampoules) softgel, tablets, capsules and ointments all with aim of USFDA, TGA, MHRA, EMEA and cGMP certification. This Unit will have the approval of –
1. USFDA - USA
2. MHRA - UK
3. TGA - Australia
4. EMEA - Europe
5. cGMP - WHO
6. MCC - South Africa
7. ANVISA – Brazil
Arvind Remedies Ltd Stock Will go 5.5/- to 7.5/- range in Short term and Medium Term,
For 2010-11 June Quarter Posted Net Income of 82 Cr and Net Profit of 5.9 Cr with Equity 26 Cr. As per This EPS is 1/- Annualized But in coming Quarters Expanding Income will add So Expecting EPS for 2010-11 is 1.5/-. Stock Trading at 2.3/- PE just 2 Industry PE is 25. As per this Stock will zoom to 15/- +++ levels in 1 year time.
A Long Term Story….........ARL Manufacturing Unit -2 ( US FDA ) ready by March 2011
Arvind Remedies Limited to be a Global Player in the Pharmaceutical Industry by Manufacturing and Marketing Quality Medicinal Products both in Allopathy and Ayurveda.
Arvind Remedies Limited set out to manufacture and market world-class allopathic and ayurvedic pharmaceutical products within and outside India, thus beginning to realize the vision of bringing high quality healthcare to the common man. Since then, we have come a long way. Having grown notably in terms of production capacity, product categories, market share, advancements in R & D, market reach and global acceptance, we are today a significant force to reckon with in the Indian Pharmaceutical Industry.
Unit 2 is located in the area of 1,65,528 square feet (3.8 acres) of land allotted at plot No.G28 & G29, SIPCOT Industrial Park, Irungattukottai, Kanchipuram District, Tamil Nadu which is on the Chennai-Bangalore Highway, 34 km from Chennai. The site is accessible from existing Chennai Airport and Sriperumbudur Airport (Proposed). The estimated cost of project is to the tune of $ 55 Million (Rs.250 Crores) and it will provide employment opportunity to around 500 persons The project is being implemented to manufacture principally, the injectables (vials and ampoules) softgel, tablets, capsules and ointments all with aim of USFDA, TGA, MHRA, EMEA and cGMP certification.
Salient Features of this unit
Tablets 1.8 billion
Capsules 450 million
Liquids 15 million
Ointments 30 million
Injectables
Ampoules 15 million
Vials 30 million
Factory location advantages are
1. Proximity to Chennai renders easy availability of qualified and skilled manpower, raw materials, packaging materials, consumables and support services like transportation, repair and other facilities
2.Existing production facilities of the company at Kakkalur is just 25 km from the unit
3.Power infrastructure is well developed within the industrial park
4.Adequate supply of water by SIPCOT
5.Well developed sewage and effluent drainage exists in the industrial park
6.Good Environmental Structure given by SIPCOT for Manufacturing the Products
As per the schedule of implementation, the project will be ready for commissioning by March 2011
Arvind Research Centre (ARC) boasts of a sophisticated Research & Development Laboratory well-equipped with the latest Technologies and Machineries.
Arvind Remedies Limited well-qualified and committed R&D Team of over 15 Research Scientists, Doctors, Ayurvedic Specialists and Chemists are the primary driving force in our R&D efforts.
Arvind Remedies Limited focus areas are Development of Drug Delivery Systems, New Formulations, Process Development of Various Dosage Forms. The six major areas where R&D works on are:
1. Ayurvedic Formulation Development
2. Allopathic Formulation Development
3. Process Development and Validation
4. Novel drugs delivery development
5. Nutraceuticals
6. Analytical Development.
Today, the Indian Pharmaceutical industry is on the verge of undergoing a paradigm shift. While preparing to meet the challenges of product patent regime, it is reformulating its growth strategies to make its mark in the global arena. The foundations of this are based in solid research, which is the crux of any technological innovation.
Arvind Remedies Limited high-tech research center has been set up at Kakkalur, Tamil Nadu for the enhancement of research capabilities with focus on the core areas of Diabetology, Cardiology and Nephrology using age-old Herbal Medicines, Nutraceuticals and anti infective segments.
Key Focus Areas and Products
In the Diabetology segment, PANKARE a herbal combination is found as an efficient treatment for Diabetes developed by our R&D. PANKARE Tablets is a scientifically and clinically developed herbal formulation for treatment of Diabetes and offers restoration, regeneration and rejuvenation of pancreatic beta cells. It also possesses anti-oxidant, anti-hypertensive and hypocholesterolmic properties.
In the Cardiology segment, ARC 1056, a Herbal combination was developed to treat Coronary Artery Disease and cure Cardio Vascular Problems, ARC 1056 has entered Phase II clinical trials after successful completion of Phase I clinical studies with the increase in the incidents of Cardio Vascular problems, owing to stressful modern day lifestyle, this segment holds great potential for development.
In the Nephrology segment, ARC 2098, a herbal combination indicated for patients undergoing dialysis has entered Phase I of clinical trial.
In the Dermatology segment, Sorexil brings solace to the un-addressed problem of Bedsores in chronic bedridden patients. It is an indigenous combination of Aloe, Neem Oil, Castor Oil with PMFA Technology and offers relief from Bedsores, Diabetic Ulcers, Pressure Sores, Venous Ulcers, Burns, Cuts and Wounds. Besides healing wounds, Sorexil leaves lesser marks and no Keloids. Arvind Remedies Limited are perhaps the first Company to introduce a cure for Bed sores, through this Ayurvedic product in the form of trans dermal delivery.
Another herbal combination indicated for wound dressings, ARC 190, is in the Phase II clinical trials. This product is an extension of Sorexil. ARC 190 dressings with Sorexil gel is a revolution in this area. So far the Clinical trials have shown excellent results. Surgical wound dressing has a huge market potential of over Rs.300 Crores and the need is enormous. This product is a boon to Surgeons and to suffering patients.
Arvind Remedies Limited have two unique products of solufact'O' & solufact'C' which are proven for its efficiency in reducing weight promisingly in obese people and help in controlling blood chloesterols. Both are clinically proven in Phase II.
In Nutraceuticals, we are developing products for Pregnant Women, Diabetics, Geriatrics and Cardiac patients.
R & D pipeline has a number of Herbal products, in the development stage, and a new Herbal Product is expected to be launched every 9 to 12 months.
Arvind Remedies Limited having Lot Expansion Plans in Fututre. Its a Multibagger stock. Just buy and hold 1 year will get 5 times Return like SE Investments Ltd (This Stock I have Recommended at 175/- levels after that reached 1200/- levels including Bonus and Split).
Positive Points for this stock for Up moving:
1) Company is in Pharma Business; company Circle people and Operators are accumulating at current price. Because Company Stock Good Value at 2.3/- Good Profit making company and Good dividend paying company.
2) Equity is very small at 25 Cr promoters Holding 25%
3) Company recently going Expansion Plans Unit 2 and aim of USFDA, TGA, MHRA, EMEA and cGMP certification.
4) Good Profit Making Company for 20010-11 EPS 1/- Annualised and Expecting EPS for full year is above 1.5/-because Expansion income will add next Quarters.
5) Company having Good Land Bank and Good Assets.
6) Company having lot of Expansion Plans in Future .
7) FII's Eyes in this stock. If they will start buy Stock will zoom to 5/- to 15/- levels
8) Risk Free at Current Market Price, Its very Cheap price Trading at 2.3/- Compare to companies Reserves, Assets and Value and Equity and Profits and Future Plans.
9) This Stock is not Participated this Market Rally. So Operators and FII';s eye's in this stock.
Happy Invest … Good Fundamental CALL and will give good returns & BEFORE INVESTING PLEASE READ ALSO MY DISCLAIMER LABEL.
"HAPPY DIWALI TO ALL OF U "
